

## Research article

## Open Access

**pO polarography, contrast enhanced color duplex sonography (CDS), [<sup>18</sup>F] fluoromisonidazole and [<sup>18</sup>F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?**

Bernd Gagel\*<sup>1</sup>, Marc Piroth<sup>1</sup>, Michael Pinkawa<sup>1</sup>, Patrick Reinartz<sup>2</sup>, Michael Zimny<sup>2</sup>, Hans J Kaiser<sup>2</sup>, Sven Stanzel<sup>3</sup>, Branka Asadpour<sup>1</sup>, Cengiz Demirel<sup>1</sup>, Kurt Hamacher<sup>4</sup>, Heinz H Coenen<sup>4</sup>, Thomas Scholbach<sup>5</sup>, Payam Maneschi<sup>6</sup>, Ercole DiMartino<sup>6</sup> and Michael J Eble<sup>1</sup>

Address: <sup>1</sup>Department of Radiotherapy, RWTH Aachen University, Germany, <sup>2</sup>Department of Nuclear Medicine, RWTH Aachen University, Germany, <sup>3</sup>Institute of Medical Statistics, RWTH Aachen University, Germany, <sup>4</sup>Institute of Nuclear Chemistry, Research Center Juelich, Germany, <sup>5</sup>Department of Pediatrics, Hospital St.Georg, Leipzig, Germany and <sup>6</sup>Department of Otorhinolaryngology and Plastic Head and Neck Surgery, DIAKO, Bremen, Germany

Email: Bernd Gagel\* - [BGagel@UKAachen.de](mailto:BGagel@UKAachen.de); Marc Piroth - [MPiroth@UKAachen.de](mailto:MPiroth@UKAachen.de); Michael Pinkawa - [MPinkawa@UKAachen.de](mailto:MPinkawa@UKAachen.de); Patrick Reinartz - [preinartz@compuserve.com](mailto:preinartz@compuserve.com); Michael Zimny - [zimny@nuklearmedizin-hanau.de](mailto:zimny@nuklearmedizin-hanau.de); Hans J Kaiser - [HJKaiser@UKAachen.de](mailto:HJKaiser@UKAachen.de); Sven Stanzel - [SStanzel@medfak.rwth-aachen.de](mailto:SStanzel@medfak.rwth-aachen.de); Branka Asadpour - [BAsadpour@UKAachen.de](mailto:BAsadpour@UKAachen.de); Cengiz Demirel - [CDemirel@UKAachen.de](mailto:CDemirel@UKAachen.de); Kurt Hamacher - [H.Hamacher@fz-juelich.de](mailto:H.Hamacher@fz-juelich.de); Heinz H Coenen - [H.H.Coenen@fz-juelich.de](mailto:H.H.Coenen@fz-juelich.de); Thomas Scholbach - [thomas.scholbach@sanktgeorg.de](mailto:thomas.scholbach@sanktgeorg.de); Payam Maneschi - [payamm@gmx.de](mailto:payamm@gmx.de); Ercole DiMartino - [Mdimartino@aol.de](mailto:Mdimartino@aol.de); Michael J Eble - [MEble@UKAachen.de](mailto:MEble@UKAachen.de)

\* Corresponding author

Published: 28 June 2007

Received: 13 November 2006

BMC Cancer 2007, 7:113 doi:10.1186/1471-2407-7-113

Accepted: 28 June 2007

This article is available from: <http://www.biomedcentral.com/1471-2407/7/113>

© 2007 Gagel et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

**Background:** The present study was conducted to analyze the value of ([<sup>18</sup>F] fluoromisonidazole (FMISO) and [<sup>18</sup>F]-2-fluoro-2'-deoxyglucose (FDG) PET as well as color pixel density (CPD) and tumor perfusion (TP) assessed by color duplex sonography (CDS) for determination of therapeutic relevant hypoxia. As a standard for measuring tissue oxygenation in human tumors, the invasive, computerized polarographic needle electrode system (pO<sub>2</sub> histography) was used for comparing the different non invasive measurements.

**Methods:** Until now a total of 38 Patients with malignancies of the head and neck were examined. Tumor tissue pO<sub>2</sub> was measured using a pO<sub>2</sub>-histograph. The needle electrode was placed CT-controlled in the tumor without general or local anesthesia. To assess the biological and clinical relevance of oxygenation measurement, the relative frequency of pO<sub>2</sub> readings, with values ≤ 2.5, ≤ 5.0 and ≤ 10.0 mmHg, as well as mean and median pO<sub>2</sub> were stated. FMISO PET consisted of one static scan of the relevant region, performed 120 min after intravenous administration. FMISO tumor to muscle ratios (FMISO<sub>T/M</sub>) and tumor to blood ratios (FMISO<sub>T/B</sub>) were calculated. FDG PET of the lymph node metastases was performed 71 ± 17 min after intravenous administration. To visualize as many vessels as possible by CDS, a contrast enhancer (Levovist®, Schering Corp., Germany) was administered. Color pixel density (CPD) was defined as the ratio of colored to grey

pixels in a region of interest. From CDS signals two parameters were extracted: color hue – defining velocity ( $v$ ) and color area – defining perfused area ( $A$ ). Signal intensity as a measure of tissue perfusion (TP) was quantified as follows:  $TP = v_{\text{mean}} \times A_{\text{mean}}$ .

**Results:** In order to investigate the degree of linear association, we calculated the Pearson correlation coefficient. Slight ( $|r| > 0.4$ ) to moderate ( $|r| > 0.6$ ) correlation was found between the parameters of  $pO_2$  polarography ( $pO_2$  readings with values  $\leq 2.5$ ,  $\leq 5.0$  and  $\leq 10.0$  mmHg, as well as median  $pO_2$ ), CPD and FMISO- $T/M$ . Only a slight correlation between TP and the fraction of  $pO_2$  values  $\leq 10.0$  mmHg, median and mean  $pO_2$  could be detected. After exclusion of four outliers the absolute values of the Pearson correlation coefficients increased clearly. There was no relevant association between mean or maximum FDG uptake and the different polarographic- as well as the CDS parameters.

**Conclusion:** CDS and FMISO PET represent different approaches for estimation of therapy relevant tumor hypoxia. Each of these approaches is methodologically limited, making evaluation of clinical potential in prospective studies necessary.

## Background

Tumor hypoxia has been associated with malignant progression, representing an increasing probability of recurrence, loco regional spread and distant metastases. In addition, the hypoxic fraction in solid tumors reduces their sensitivity to conventional treatment modalities, modulating therapeutic response to ionizing radiation or certain chemotherapeutic agents [5,8,10,25]. Consequently detection and monitoring of tissue oxygenation can be important for modifying therapeutic strategies, including local dose escalation for radiotherapy or selection of chemotherapeutic agents with better impact even in hypoxic tumors. The causes of tumor hypoxia are complex including multiple factors determining tumor blood flow such as perfusion pressure, viscous and geometric resistance to flow, arteriovenous shunts and interstitial fluid flow.

Numerous different approaches have been made to identify hypoxia in tumors [12,13]. The computerized polarographic needle electrode system ( $pO_2$  histography) represents one standard for measuring tissue oxygenation in human malignancies [28]. However, it is an invasive method being confined to superficial, well accessible tumors or lymph node metastases.

A non-invasive approach to detect hypoxia in tumors is the positron emission tomography (PET) with nitroimidazole derivatives. Nitroimidazoles are recognized to bind selectively to hypoxic cells [23] and are reduced intracellular. In hypoxic cells re-oxidation is hindered, leading to intracellular accumulation of nitroimidazole. Radiolabelled nitroimidazole used in positron emission tomography is therefore highly suitable to determine tumor tissue oxygenation.

We present the results of our analyses of a cohort of patients with head and neck malignancies, being examined with direct, invasive measurements of tissue oxygenation by  $pO_2$  polarography and non-invasive [ $^{18}F$ ] Fluoromisonidazole (FMISO) and [ $^{18}F$ ] Fluorodeoxyglucose (FDG) positron-emission-tomography (PET) for determination of tumor oxygenation. In addition two factors related to oxygen delivery, the tumor vascularisation and tumor perfusion were measured by contrast-enhanced color duplex sonography (CDS).

## Methods

### Patients

Lymph node metastases of 38 patients with histologically verified head and neck malignancies (36 patients with squamous cell cancer, one patient with lympho-epithelial cancer and one patient with Hodgkin's lymphoma) were enrolled in a prospective clinical evaluation between October 2002 and January 2005. Standard sonographic, CT and PET criteria were used for the diagnosis of metastatic lymph nodes. In 20 patients the diagnosis was confirmed histologically. Patients underwent the following measurements within one week: contrast-enhanced color duplex sonography (CDS), FDGPET, FMISOPET and polarographic  $pO_2$  measurement (last measurement). None of the patients had previously been treated for their malignancies. Because of different treatment modalities (surgery followed by radio- or radio-/chemotherapy, primary radio-/chemotherapy and chemotherapy alone) no clinical analysis was performed. The study was approved by the medical ethical committee of the University Aachen, Germany. After explanation of the rationale, risks, and benefits of the examination, informed consent was obtained from all patients.

Measurements were performed in one lymph node metastases in each patient. In order to ensure measurements in

the same suspected lymph nodes, sonographically examined lymph nodes were marked on diagnostic CT scans or in the case of lymph node conglomerates, the extension of the scanned node was marked on skin. PET examinations were realized in most of the patients within two days (maximum time interval four days) using skin markers and positioning lasers for reproducible data acquisition resulting in a corresponding slice location. No immobilization device was used. Sonographic studies, selection of representative images and parameter calculation as well as polarographic measurement were performed by one person each respectively, resulting in an objective and independent data acquisition. As detailed information of all used techniques was published by our group [3,6,27,34] only a description of the essential aspects of the different measurement procedures is given.

#### **Color Duplex Sonography (CDS)**

Technical details and adjustment of the sonography device were used as previously published [3,6,27]. In order to visualize as many vessels as possible a contrast enhancer (Levovist, Schering Corp., Berlin, Germany) was administered. We used a solution of 4 g Levovist® in 11 ml sterile water for injection. 5.5 ml were given as a bolus whereas 5.5 ml were infused with 300 ml/h. CDS was performed in 32 patients.

#### **Color pixel density (CPD)**

This examination could be realized in 32 patients. All sonographic studies were recorded on digital video. From these video recordings, representative horizontal and longitudinal scans were selected for assessment. Depending on the size of the investigated nodes, this resulted in 5 to 16 (mean = 8.13; standard deviation (SD) = 4.38) images of each lymph node. For visualization of tumor vascularisation, the maximal systolic phases were used. Sonographic studies, selection of representative images and parameter calculation were performed by one person each, respectively. In a region of interest, representing the extent of vascularisation in the investigated slice, CPD was defined as ratio of colored pixels to gray pixels. The mean CPD was calculated in order to find a representative value for imaged vascularisation.

#### **Quantification of perfusion**

In the course of the study the commercially software (PixelFlux®, Chameleon-Software Corp., Leipzig, Germany) was available. In 18 patients this software was used for evaluation of blood flow dynamics in the lymph node metastases until now. Cervical lymph nodes were examined at the largest diameter to record perfusion signals of intranodal vessels. All sonographic studies were recorded and perfusion signals of every single image were read out automatically from the region of interest (ROI). The ROI

was defined in advance, encompassing the whole node's area, sparing out surrounding tissue.

The new technique allows a simultaneous measurement of the classical resistance index (RI) and pulsatility index (PI) in all vessels of the region of interest (ROI) [27]. Every single pixel in each vessel is traced through a complete heart cycle. Changes of color hue – representing flow velocity at this point – are measured and RI as well as PI is calculated. By this approach tissue-RI (TRI) and tissue-PI (TPI) for each point of a complete heart cycle were calculated, representing mean PI and RI of all vessels inside the ROI. Signal intensity as a measure of tissue perfusion (TP) was quantified as follows:  $TP = v_{\text{mean}} \times A_{\text{mean}}$  with  $A$  = part of the ROI filled with color signals and  $v$  = velocity values of all pixels inside the ROI changing due to heart action.

#### **Positron-Emission-Tomography (PET)**

In 24 patients FDG PET as well as FMISO PET examinations could be performed. All PET studies were carried out using an ECAT EXACT 922/47® scanner with an axial field of view of 16.2 cm (Siemens CTI, Knoxville, TN, USA). The spatial resolution in the transaxial and axial orientation of this PET is nearly isotropic. In the reconstructed images, the full width at half maximum (FWHM) is about 6.0 mm measured at the center of the field of view (FOV) using a ramp filter with a 0.5 cut-off frequency.

FDG PET of the tumor region was performed  $71 \pm 17$  min after intravenous administration of  $264 \pm 46$  MBq FDG, applying the whole-body tool with 8 min emission scanning and 4 min transmission scanning for each bed position. After correction for attenuation using the transmission scan optimized by a segment  $\mu$ -map with empirical attenuation coefficients, the data were reconstructed with the OSEM algorithm [14]. All patients fasted for at least 6 h before examination, verified by determining blood glucose level (mean = 90.8 mg/dl; SD = 16.0 mg/dl). None of the patients showed a higher concentration than 120 mg/dl, so treatment with insulin prior to examination was not necessary.

FMISO PET consisted of one static scan of the relevant region – as defined by sonography or computed tomography – performed 120 min after intravenous administration of  $314 \pm 42$  MBq FMISO. The acquisition time included 15 min emission scanning followed by 4 min transmission scanning. Attenuation correction and reconstruction processing was done according to FDG PET. Three venous blood samples (after 120-, 125- and 130 minutes) were taken at each static scan. After correction according to the half-life period the mean values were calculated. The radioactivity concentration was measured in a calibrated well counter (Spectrum Master 92X, EG&G

Ortec, Oak Ridge, TN). After correction for decay the mean values were calculated.

The tumor was defined according to the image data of the FDG-PET and the puncture computer tomography (CT) scans. In cases where the tumour was not clearly visible in the FMISO scan, FDG data were used to delineate the malignant lesion and define a region of interest. Rectangular regions of interest depending to the tumor size were placed over the tumor and ipsilateral nuchal muscles in order to calculate FMISO tumor to muscle ratios ( $FMISO_{T/M}$ ). To calculate tumor to blood ratios ( $FMISO_{T/B}$ ) at 120 min after administration of FMISO, the average radioactivity concentration of the three blood samples was used.

For FDG PET, mean and maximum standardized uptake values (SUV) of the tumor were calculated after normalization of the radioactivity concentration to the injected radioactivity and the body weight. Additionally, the mean SUV was approximately corrected for partial volume effects by applying recovery coefficients obtained from phantom studies [14]...

#### **Polarographic pO<sub>2</sub> measurement**

Tumor oxygenation was measured in 36 patients with polarographic needle electrodes, using a pO<sub>2</sub>-histograph (Eppendorf, Hamburg, Germany). Sterile polarographic needle electrodes with stainless steel shafts and a mean diameter of 300 µm were used. For each patient the needle electrodes were placed and guided CT-controlled in the tumor after visual matching of CT- and PET-scans without general or local anesthesia, avoiding larger necrotic areas by preceding diagnostic CT scans. In this way we realized 95–400 single pO<sub>2</sub> measurements per lymph node (mean = 225; SD = 61) resulting in a representative distribution of pO<sub>2</sub> values. The relative frequency of pO<sub>2</sub> readings with values ≤ 2.5 mmHg, ≤ 5.0 mmHg and ≤ 10.0 mmHg as well as mean and median pO<sub>2</sub> were calculated to assess the biological and clinical relevance of oxygenation measurement [30].

#### **Statistical methods**

Data are summarized by calculating relative frequencies, as well as suitable measurements of location and variation. The degree of linear relationship between different, polarographically measured parameters of tumor hypoxia, CPD, TP and the FDG-, and FMISO-PET parameters investigated by computing Pearson correlation coefficients and displayed graphically using scatter plots.

All statistical analyses were performed using the SPSS® 12.0 statistical analysis software package.

## **Results**

### **Color Duplex Sonography**

The interindividual range of mean color pixel density in the investigated lymph nodes was between 2.4% and 16.4% (mean = 8.1%; SD = 2.4%). The average TP was 0.065 cm/s with a range from 0.012 cm/s to 0.173 cm/s and a SD of 0.051 cm/s. A mean number of 8.0 (range: 5–16; SD = 4.4) recorded slices per measurement were evaluated.

### **Positron-Emission-Tomography**

Mean and maximum SUV of FMISO (average  $FMISO_{SUVmean} = 1.69$ , SD = 0.40; average  $FMISO_{SUVmax} = 1.98$ , SD = 0.50) and FDG (average  $FDG_{SUVmean} = 8.13$ , SD = 3.45; average  $FDG_{SUVmax} = 9.79$ , SD = 4.41) as well as tumor-to-muscle ratios of FMISO (average  $FMISO_{T/M} = 1.57$ , SD = 0.34) and tumor-to-blood ratios of FMISO (average  $FMISO_{T/B} = 1.13$ , SD = 0.25) were calculated for the total tumor regions.

### **Polarographic pO<sub>2</sub> measurement**

The average median pO<sub>2</sub> was 12.5 mmHg (range: 0.1–41.1 mmHg; SD = 10.3 mmHg). The average mean pO<sub>2</sub> was 17.6 mmHg (range: 8.8–36.0 mmHg; SD = 7.3 mmHg). The mean proportion of pO<sub>2</sub> values ≤ 2.5 mmHg was 29.3% (range: 0.0–58.5%; SD = 18.4%), of values ≤ 5.0 mmHg 38.4% (range: 7.0–73.6%; SD = 18.1%) and of values ≤ 10.0 mmHg 48.9% (range: 13.0–78.7%; 18.2%).

### **Correlations**

In order to detect possible relations between the different relevant polarographically measured parameters of tumor hypoxia,  $FMISO_{T/M}$ ,  $FMISO_{T/B}$ , CPD and TP, we calculated the Pearson correlation coefficient. Correlations are listed in Table 1. To emphasize relevant correlations ( $r > 0.4$ ) bold numbers were used. Only a slight association between  $FMISO_{T/B}$  and the hypoxic fraction ≤ 2.5 mmHg could be detected. There was no relevant correlation between  $FMISO_{T/B}$  and the other polarographically, as well as sonographically, measured parameters. There was also no relevant association between TP and the hypoxic fractions ≤ 2.5 mmHg as well as ≤ 5.0 mmHg. When graphically analyzing the observed correlations through an evaluation of the corresponding scatter plots (Figure 1), there were two patients (patient1; patient2) with obviously low color pixel density, and mean/median pO<sub>2</sub> values based on inhomogeneous distribution of the different hypoxic fractions with a high percentage of readings ≤ 10 mmHg and low percentage of readings ≤ 2.5 or ≤ 5.0 mmHg.

In addition there were two patients (patient3; patient4) with apparent discrepancy between FMISO uptake and pO<sub>2</sub>-polarography. Re-evaluation of these patients revealed small, mostly necrotic lymph node metastases

**Table 1: Correlations between different relevant polarographically measured parameters of tumor hypoxia, FMISO PET, CDS and FDG PET data based oxygenation values**

	≤2.5 mmHg	≤5.0 mmHg	≤10.0 mmHg	Median pO <sub>2</sub>	Mean pO <sub>2</sub>	FMISO <sub>T/M</sub>	FMISO <sub>T/B</sub>	CPD	TP	FDG <sub>SUVmax</sub>	FDG <sub>SUVmean</sub>
≤2.5 mmHg						<b>r = 0.746</b>	<b>r = 0.476</b>	<b>r = -0.735</b>	<i>r = -0.355</i>	<i>r = 0.302</i>	<i>r = 0.276</i>
N	36					20	20	28	16	20	20
≤5.0 mmHg	<b>r = 0.934</b>					<b>r = 0.757</b>	<b>r = 0.478</b>	<b>r = -0.786</b>	<b>r = -0.527</b>	<i>r = 0.161</i>	<i>r = 0.123</i>
N	36	36				20	20	28	16	20	20
≤10.0 mmHg	<b>r = 0.765</b>	<b>r = 0.903</b>				<b>r = 0.703</b>	<b>r = 0.435</b>	<b>r = -0.788</b>	<b>r = -0.604</b>	<i>r = 0.021</i>	<i>r = -0.013</i>
N	36	36	36			20	20	28	16	20	20
Mean pO <sub>2</sub>	<b>r = -0.610</b>	<b>r = -0.768</b>	<b>r = -0.902</b>			<b>r = -0.589</b>	<i>r = -0.278</i>	<b>r = 0.720</b>	<b>r = 0.607</b>	<i>r = 0.167</i>	<i>r = 0.174</i>
N	36	36	36	36		20	20	28	16	20	20
Mean pO <sub>2</sub>	<b>r = -0.485</b>	<b>r = -0.676</b>	<b>r = -0.837</b>	<b>r = 0.923</b>		<b>r = -0.582</b>	<i>r = -0.272</i>	<b>r = 0.576</b>	<b>r = 0.508</b>	<i>r = 0.166</i>	<i>r = 0.161</i>
N	36	36	36	36	36	20	20	28	16	20	20
FMISO <sub>T/M</sub>	<b>r = 0.558</b>	<b>r = 0.551</b>	<b>r = 0.462</b>	<b>r = -0.413</b>	<i>r = -0.376</i>						
N	22	22	22	22	22	24					
FMISO <sub>T/B</sub>	<b>r = 0.401</b>	<i>r = 0.396</i>	<i>r = 0.342</i>	<i>r = -0.215</i>	<i>r = -0.200</i>	<b>0.557</b>					
N	22	22	22	22	22	24	24				
CPD	<b>r = -0.475</b>	<b>r = -0.537</b>	<b>r = -0.662</b>	<b>r = 0.590</b>	<b>r = 0.468</b>	<b>r = -0.503</b>	<i>r = -0.270</i>				
N	31	31	31	31	31	18	18	32			
TP	<i>r = -0.145</i>	<i>r = -0.303</i>	<b>r = -0.592</b>	<b>r = 0.604</b>	<b>r = 0.519</b>	<b>r = -0.509</b>	<i>r = 0.004</i>	<b>r = 0.784</b>			
N	18	18	18	18	18	9	9	18	18		
FDG <sub>SUVmax</sub>	<i>r = 0.241</i>	<i>r = 0.101</i>	<i>r = -0.056</i>	<i>R = 0.205</i>	<i>r = 0.219</i>	<i>r = 0.159</i>	<b>r = 0.403</b>	<i>r = 0.105</i>	<i>r = 0.179</i>		
N	22	22	22	22	22	24	24	18	9	24	
FDG <sub>SUVmean</sub>	<i>r = 0.238</i>	<i>r = 0.087</i>	<i>r = -0.062</i>	<i>R = 0.193</i>	<i>r = 0.193</i>	<i>r = 0.108</i>	<i>r = 0.329</i>	<i>r = -0.077</i>	<i>r = 0.103</i>	<b>r = 0.982</b>	
N	22	22	22	22	22	24	24	18	9	24	24

Correlations after exclusion of outliers in the marked right upper columns of the table; relevant correlation marked by bold numbers; *r* = Pearson coefficient of correlation; N = number of correlated measurements.

with only a small amount of vital tumor tissue and in one case with margining high perfused vessels. After exclusion of these outliers, the absolute value of the corresponding Pearson correlation coefficients increased clearly as shown in Table 1 in the right upper columns.


There was no relevant association between mean or maximum FDG uptake and the different polarographic- as well as the CDS parameters with an absolute value of the Pearson correlation coefficient ranging between 0.056 and 0.241. There was only a moderate association between FMISO<sub>T/B</sub> and FDG<sub>SUVmax</sub> with a Pearson correlation coefficient of 0.403. No relevant correlation between FMISO<sub>SUVmax/mean</sub> and CPD/TP or the polarographic parameters could be detected. Figure 2 shows the corresponding results of pO<sub>2</sub> polarography, CDS, FDG and FMISO PET in a normoxic and a hypoxic tumor.

## Discussion

Results of preclinical and clinical investigations during the last ten years have confirmed that tumor hypoxia precedes malignant progression by several mechanisms, including an increased expression of transcription factors and gene products involved in tumor progression and induction of genomic instability. In those investigations, the transcriptional factor HIF-1 has emerged as a major regulator of adaptive processes (including angiogenesis) that can support tumor cell survival, proliferation, invasion, and tumor spread. It has also been shown that hypoxia can

enhance malignant progression and increase aggressiveness through clonal selection [31]. Numerous different approaches have been made in order to identify hypoxia in tumors for clinical use [13].

One standard method for quantifying hypoxia, although it was partly controversially discussed in literature, has been electrode measurement of tumor oxygen tension [4,24,28,29]. Several studies have shown that lower oxygenated tumors are more radio resistant [8,11]. This was recently shown in an international multi-centre study of 397 patients with squamous cell carcinomas of the head and neck [22], identifying pre-treatment tumor hypoxia as an indicator for poor overall survival after radiotherapy. Although it represents a mixture of intra- and intercellular pO<sub>2</sub> of 30 to 50 cells in front of the probe and not a direct measurement of intracellular oxygenation, it enables an estimation of radio biologically relevant intracellular oxygenation. This could be proved by the use of comet assay and pO<sub>2</sub> polarograph in anaplastic R3327-AT Dunning prostate tumors, resulting in high correlations between mean pO<sub>2</sub> and mean comet moment as a parameter of overall strand break induction [26]. Applying pO<sub>2</sub> histography, an evaluation of intratumoral oxygenation heterogeneity, but not of spatial information is possible. As an invasive method it is confined to superficial, well accessible tumors or lymph node metastases. Evaluating the different methods for determination of tumor oxygenation, we found only slight to moderate correlations between




**Figure 1**

Scatter plots visualizing type of association between selected polarographic parameters (median  $pO_2$ , hypoxic fraction  $\leq 2.5$  mmHg and  $\leq 5.0$  mmHg) and color pixel density (CPD) as well as FMISO tumor to muscle ratio (FMISO<sub>T/M</sub>) after 2 h (→ marked outliers). Left graphs: scatter plots using all available data values. Right graphs: corresponding scatter plots after exclusion of marked outliers identified in the left graph.

$pO_2$  histography and most of the non-invasive measurable parameters. When analyzing the differences in correlation through an evaluation of the scatter plots (Figure 1), we were able to identify four outliers representing the limitations of the different methods.

Comparing the parameters of  $pO_2$  polarography and CPD there were two patients (patient 1 and 2) with low mean and median  $pO_2$  values based on inhomogeneous distribution of the different hypoxic fractions. There was a high percentage of readings  $\leq 10$  mmHg and a low percentage of readings  $\leq 2.5$  or  $\leq 5.0$  mmHg. CPD or TP only deliver a mean value of tumor vascularisation or perfusion. The method is therefore unable to reproduce any heterogene-



**Figure 2**

From left to right: transaxial FDG PET-, transaxial FMISO PET-, CDS- and transaxial CT scans in two different patients. A: with a normoxic tumor ( $pO_2 \leq 2.5$  mmHg = 13.0%,  $pO_2 \leq 5.0$  mmHg = 15.1%,  $pO_2 \leq 10.0$  mmHg = 17.0%, median  $pO_2$  = 36.2 mmHg, mean  $pO_2$  = 41.1 mmHg; CPD = 12.05%; FDG<sub>SUVmax</sub> = 17.84, FDG<sub>SUVmean</sub> = 14.80; FMISO<sub>T/M</sub> = 1.31, FMISO<sub>T/B</sub> = 1.07). B: with a hypoxic tumor ( $pO_2 \leq 2.5$  mmHg = 37.7%,  $pO_2 \leq 5.0$  mmHg = 48.8%,  $pO_2 \leq 10.0$  mmHg = 58.1%, median  $pO_2$  = 5.5 mmHg, mean  $pO_2$  = 17.7 mmHg; CPD = 2.71%; FDG<sub>SUVmax</sub> = 9.34, FDG<sub>SUVmean</sub> = 8.00; FMISO<sub>T/M</sub> = 1.60, FMISO<sub>T/B</sub> = 0.88). 1/2 = distance measurements for the guidance of the polarographic needle electrode

ity of tumor oxygenation resulting in a decreased correlation between CPD or TP and the hypoxic fractions  $\leq 2.5$  and  $\leq 5.0$  mmHg.


As an endpoint for reporting FMISO PET data, we used the ratio between radioactivity in the tumor and reference tissue, consisting of muscle tissue and blood as suggested by Chapman et al. and Kubota et al. [1,16]. It could be shown that the tumor uptake of FMISO was constant between 30 min and 2 h and that the tumor to blood and tumor to muscle FMISO uptake ratios were stable 2–4 h after injection suggesting some retention mechanisms of FMISO within the tumor but not within any normal tissue [16]. Analyzing patient 3, this patient revealed a mostly necrotic lymph node metastasis with only a small amount of margining vital, hyperperfused tumor tissue. Although we tried to ensure electrode measurements in vital tumor tissue by the use of computed tomography guidance, an overestimation of hypoxic fractions by  $pO_2$  polarography must be expected. Rejecting central necrotic tumor parts from CDS evaluation, we found good correlation between CDS and FMISO parameters. Patient 4 also showed an apparent discrepancy between FMISO uptake and  $pO_2$ -polarography. This patient had a lymph node metastasis with a necrotic part and a part with vital tumor tissue (Figure 3). In this case, it was possible to realize CT controlled  $pO_2$  polarography and CDS measurement in the vital tumor part. Because of the small vital tumor volume and due to the limited spatial resolution of PET data, a representative measurement of tumor oxygenation by FMISO was not possible. In contrast to CDS parameters with dis-



advantages in representation of low hypoxic fractions, there were moderate to good correlations between the different hypoxic fractions and FMISO<sub>T/M</sub>. But a decrease in the degree of linear association between FMISO<sub>T/M</sub> and mean as well as median pO<sub>2</sub> could be detected. Using <sup>3</sup>H-MISO and a monolayer cell sandwich system with V79 and 9 L cell lines, Hlatky et al. could detect a systematic decrease in the standard deviation of grains per cell when they examined populations of cells further away from the nutrient and oxygen source [9]. An accumulation of MISO below 10.0 mmHg and an inverse relationship of MISO uptake to decreased polarographically measured pO<sub>2</sub> could be expected. But even this accumulation of MISO below 10 mmHg may explain the lower correlation between FMISO<sub>T/M</sub> or FMISO<sub>T/B</sub> after 2 h and mean or median pO<sub>2</sub>, because of high pO<sub>2</sub> values leading to higher mean or median pO<sub>2</sub>, which cannot be visualized by FMISO PET. This fact was confirmed by different parameters of pO<sub>2</sub> polarography showing only slight to moderate correlations between the fraction of pO<sub>2</sub> values ≤ 2.5 mmHg and the mean or median pO<sub>2</sub>.

The hypothesis that tumor hypoxia has an effect on glucose metabolism is mainly based on experimental data using human cancer cell lines and clinical results and is discussed controversially [2,15,21,34]. Although hypoxia-inducible factor 1 alpha (HIF-1α) is a major regulator of tumor cell adaptation to hypoxic stress, increasing the expression of glycolytic enzymes and proteins [31,33], the FDG uptake was not predictive for tumor hypoxia as assessed by pO<sub>2</sub>-polarography in our series of patients.

Examining blood flow-metabolic relationships, the results analyzing perfusion parameters and glucose metabolism are contradictory [17,20]. According to the progress in tumor molecular genetics in the last decade, biological rational for association of these factors are given by p53 oncogene. The p53 oncogene is known to promote tumor angiogenesis and glucose metabolism. Tumor cells use the tumor suppressor p53, which is usually modified by mutations to debilitate cell cycle controls, to activate hexokinase gene transcription in particular the Type II isoform. This induces the capacity of tumor cells, at least in part, to catabolise glucose at high rates [18,19]. Mutant p53 might also stimulate tumor angiogenesis, indirectly by augmenting the tumor cell proliferation and directly, by up regulating angiogenic factors and down regulating angiogenic inhibitors in the same way [32]. In addition a significant association of intratumoral micro vessel density and p53 protein over expression was described in head-and-neck carcinoma [7]. However, we were not able to show an association between the vascularisation or tumor perfusion seen in CDS images and glucose metabolism as shown by FDG PET parameters, reflecting the problem of adverse effects



**Figure 3**  
Outlier patient 4, transaxial FDG PET- (A), transaxial FMISO PET- (B), CDS- (C) and transaxial CT (D) scans (pO<sub>2</sub> = 2.5 mmHg = 43.0%, pO<sub>2</sub> = 5.0 mmHg = 53.0%, pO<sub>2</sub> = 10.0 mmHg = 71.5%, median pO<sub>2</sub> = 3.7 mmHg, mean pO<sub>2</sub> = 8.8 mmHg; CPD = 2.96%; FDG<sub>SUVmax</sub> = 4.80, FDG<sub>SUVmean</sub> = 4.55; FMISO<sub>T/M</sub> = 1.19, FMISO<sub>T/B</sub> = 1.11). 1/2 = distance measurements for the guidance of the polarographic needle electrode.

such as flow based supply of oxygen and glucose, p53 gene based stimulation of tumor angiogenesis and glucose metabolism as well as hypoxia induced HIF-1α expression of glucose transport proteins and hexokinase. It reflects that tumor hypoxia is caused by innumerable, multifactorial, partly contradictory interacting causes and effects complicating detection of therapy relevant hypoxia

by the use of clinical examinations. Nevertheless those examinations may enable the transfer of simplified information from cellular micro cosmos into clinical practice.

## Conclusion

Applying CDS for the evaluation of two factors mainly influencing relevant tumor hypoxia as vascularisation (CPD) and perfusion (TP), an estimation of average tissue oxygenation without quantification of oxygenation heterogeneity was possible. The later could be realized by the FMISO parameters especially by FMISO<sub>T/M</sub> after 2 h. It facilitated spatial information, but showed its limits in small tumor lesions caused by spatial resolution of the PET scanner. Although FDG uptake may increase under hypoxic conditions, it could not reliably differentiate hypoxic from normoxic tumors.

Clinical relevance of polarographic determination of tumor oxygenation was elucidated in several clinical studies. But recently the emphasis has been on the potential use of non-invasive approaches. CDS and FMISO PET for estimation of therapy relevant tumor hypoxia represent different non invasive approaches for analysis of tumor hypoxia. But each of these approaches is methodologically limited. Consequently clinical potential must be substantiated in a prospective study, including uniform treatment modalities in order to be more than only bricks in the puzzle of therapy relevant tumor hypoxia.

## Competing interests

Financial competing interests

The pharmaceutical company Hoffmann- La Roche partially financed the costs for FMISO, a substance used to carry out PET scans.

The authors declare that there are no other competing interests.

## Authors' contributions

BG has made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; MP has been involved in acquisition of data; MP has been involved in acquisition of data; PR has made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data; MZ has made substantial contributions to conception and design, acquisition of data; HJK has been involved in acquisition of data, analysis and interpretation of data; SS has been involved in statistical analysis and interpretation of data; BA has been involved in acquisition of data; CD has made substantial contributions to conception and design; KH has made contributions to conception and design, GMP production of tracer; HHC has made contributions to conception and design, GMP production of tracer; TS

acquisition of data, analysis and interpretation of data; PM acquisition of data, analysis and interpretation of data; ED acquisition of data, analysis and interpretation of data; MJE has been involved in analysis and interpretation of data and has made contributions to conception and design.

All authors read and approved the final manuscript.

## Acknowledgements

This study was supported financially, in management, and scientifically by F.Hoffmann-La Roche. We would like to thank the staff who took care of our patients' needs, and who were involved in gathering, documenting, verifying, forwarding, and processing the clinical data.

## References

1. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE: **Measuring hypoxia and predicting tumor radio resistance with nuclear medicine assays.** *Radiother Oncol* 1998, **46**:229-237.
2. Clavo AC, Brown RS, Wahl RL: **Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.** *J Nucl Med* 1995, **36**:1625-1632.
3. Di Martino E, Gagel B, Schramm O, Maneschi P, Westhofen M: **Evaluation of tumor oxygenation by color duplex sonography: A new approach.** *Otolaryngol Head Neck Surg* 2005, **132**:765-769.
4. Eriksen JG, Horsman MR: **Tumor hypoxia – a characteristic feature with a complex molecular background.** *Radiother Oncol* 2006, **81**:119-121.
5. Evans NTS, Naylor PFD: **The effect of oxygen breathing and radiotherapy upon tissue oxygen tension of some human tumors.** *Br J Radiol* 1963, **36**:418-425.
6. Gagel B, DiMartino E, Schramm O, Pinkawa M, Piroth M, Demirel C, Maneschi P, Stanzel S, Asadpuor B, Westhofen M, Eble MJ: **Contrast-enhanced color duplex sonography (CDS): an alternative for the evaluation of therapy-relevant tumor oxygenation?** *Strahlenther Onkol* 2006, **10**:604-609.
7. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P: **Intratumoral microvessel density and p53 protein: Correlation with metastasis in head-and-neck squamous-cell carcinoma.** *Int J Cancer* 1993, **55**:739-744.
8. Gray LH, Conger AD, Ebert M: **The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy.** *Br J Radiol* 1953, **26**:638-642.
9. Hlatky L, Alpen EL: **Two dimensional diffusion limited system for cell growth.** *Cell Tissue Kinet* 1985, **18**:597-611.
10. Höckel M, Schlegel K, Aral B, Mitze M, Schäffer U, Vaupel P: **Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix.** *Cancer Res* 1996, **56**:4509-4515.
11. Horsman MR, Overgaard J: **Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.** *Radiother Oncol* 2004, **70**:301-309.
12. Horsman MR, Overgaard J: **The oxygen effect and tumour microenvironment.** Edited by: Steel GG. Basic clinical radiobiology, Arnold, London; 2002:58-168.
13. Horsman MR: **Measurement of tumor oxygenation.** *Int J Radiat Oncol Biol Phys* 1998, **42**:701-704.
14. Hudson HM, Larkin RS: **Accelerated image reconstruction using ordered subsets of projection data.** *IEEE Trans Med Imaging* 1994, **13**:601-609.
15. Kallinowski F, Brownell AL, Vaupel P, Brownell GL: **Combined tissue oxygen tension measurement and positron emission tomography studies on glucose utilization in oncogene-transformed cell line tumour xenografts in nude mice.** *Br J Radiol* 1991, **64**:350-359.
16. Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, Sato K, Fukuda H, Ido T: **Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue.** *Eur J Nucl Med* 1999, **26**:750-757.
17. Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grenman R, Minn H: **Imaging perfusion and hypoxia with PET**



- to predict radiotherapy response in head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2004, **59**:971-982.
18. Mathupala SP, Heese C, Pedersen PL: **Glucose catabolism in cancer cells: the type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53.** *J Biol Chem* 1997, **272**:22776-22780.
  19. Mathupala SP, Rempel A, Pedersen PL: **Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase.** *J Biol Chem* 1995, **270**:16918-19925.
  20. Miles KA, Griffiths MR, Fuentes MA: **Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules.** *Radiology* 2001, **220**:548-553.
  21. Minn H, Clavo AC, Wahl RL: **Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging.** *Nucl Med Biol* 1996, **23**:941-946.
  22. Nordmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J: **Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.** *Radiother Oncol* 2005, **77**:18-24.
  23. Nunn A, Linder K, Strauss HW: **Nitroimidazoles and imaging hypoxia.** *Eur J Nucl Med* 1995, **22**:265-280.
  24. Piert M, Machulla H-J, Picchio M, Reischl G, Ziegler S, Kumar P, Wester H-J, Beck R, McEwan AJB, Wiebe LI, Schwaiger M: **Hypoxia-specific tumor imaging with 18F-Fluoroazomycin Arabinoside.** *J Nucl Med* 2005, **46**:106-113.
  25. Raleigh JA: **Hypoxia and its clinical significance.** Volume 6. Edited by: Tepper JE, Raleigh JA. Seminars in radiation oncology, Saunders, Orlando, Flo :1-70.
  26. Sauer G, Weber KJ, Eble MJ: **Comet-Assay Measurement of hypoxia correlates with preirradiation micro-electrode histography in R3327-AT rodent tumors.** *Radiat Res* 2000, **154**(4):439-446.
  27. Scholbach T, Scholbach J, Krombach GA, Gagel B, Maneschi P, DiMartino E: **New method of color Doppler signal quantification in metastatic lymph nodes compared to direct polarographic measurement of tissue oxygenation.** *Int J Cancer* 2005, **114**:957-962.
  28. Stone HB, Brown JM, Philips TL, Sutherland RM: **Oxygen in human tumors: correlations between methods of measurements and response to therapy.** *Radiat Res* 1993, **136**:422-434.
  29. Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S: **Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode pO2 measurements in murine tumors.** *Int J Radiat Oncol Biol Phys* 2005, **62**:854-861.
  30. Thews O, Vaupel P: **Relevant parameters for describing the oxygenation status of solid tumours.** *Strahlenther Onkol* 1996, **172**:239-242.
  31. Vaupel P: **The role of hypoxia-induced factors in tumor progression.** *The Oncologist* 2004, **9**(Suppl 5):10-17.
  32. Vermeulen PB, Roland L, Mertens V, Van Marck E, De Bruijn EA, Van Oosterom AT, Dirix LY: **Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma.** *Microvasc Res* 1996, **51**:164-174.
  33. Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, Takei T, Tamaki N: **Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.** *J Nucl Med* 2005, **46**:675-682.
  34. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble MJ, Buell U, Reinartz P: **FDG – a marker of tumour hypoxia? A comparison with [<sup>18</sup>F]-Fluoromisonidazole and pO<sub>2</sub>-Polarography in metastatic head and neck cancer.** *Eur J Nucl Med Mol Imaging* 2006, **33**:1426-1431.

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/7/113/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

